"The ARC said that was a flaw in the [old] definition that prevented an accurate assessment of stent thrombosis risk. Moreover, the flaw benefited bare metal stents that have much higher target vessel revascularization rate than drug-eluting stents."
Thanks Bridge, that clarifies many issues. Amazing.
Market Data 
Markets 
